These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 28825151)

  • 1. The role of gene polymorphisms and AMH level in prediction of poor ovarian response in Egyptian women undergoing IVF procedure.
    Motawi TMK; Rizk SM; Maurice NW; Maged AM; Raslan AN; Sawaf AH
    J Assist Reprod Genet; 2017 Dec; 34(12):1659-1666. PubMed ID: 28825151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Could polymorphisms of some hormonal receptor genes, involved in folliculogenesis help in predicting patient response to controlled ovarian stimulation?
    Čuš M; Vlaisavljević V; Repnik K; Potočnik U; Kovačič B
    J Assist Reprod Genet; 2019 Jan; 36(1):47-55. PubMed ID: 30406448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of FSHR rs6165 and ESR2 rs4986938 polymorphisms in ovarian stimulation of Iranian women who underwent assisted reproduction treatment.
    Kaviani M; Ghaderian SMH; Arefi S; Hashemi M; Afjeh SSA
    Hum Antibodies; 2017; 26(3):121-126. PubMed ID: 29036809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphisms influence the ovarian response to rFSH stimulation in patients undergoing in vitro fertilization programs with ICSI.
    Boudjenah R; Molina-Gomes D; Torre A; Bergere M; Bailly M; Boitrelle F; Taieb S; Wainer R; Benahmed M; de Mazancourt P; Selva J; Vialard F
    PLoS One; 2012; 7(6):e38700. PubMed ID: 22701696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial.
    Magnusson Å; Nilsson L; Oleröd G; Thurin-Kjellberg A; Bergh C
    Hum Reprod; 2017 Apr; 32(4):811-819. PubMed ID: 28175316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization.
    Nardo LG; Gelbaya TA; Wilkinson H; Roberts SA; Yates A; Pemberton P; Laing I
    Fertil Steril; 2009 Nov; 92(5):1586-93. PubMed ID: 18930213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization-intracytoplasmic sperm injection cycles with a gonadotropin-releasing hormone antagonist? A retrospective single-center study.
    Polyzos NP; Nelson SM; Stoop D; Nwoye M; Humaidan P; Anckaert E; Devroey P; Tournaye H
    Fertil Steril; 2013 Aug; 100(2):438-44. PubMed ID: 23602319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Bone Morphogenetic Protein 15 Polymorphisms to Predict Ovarian Stimulation Outcomes in Infertile Brazilian Women.
    Peluso C; Goldman C; Cavalcanti V; Gastaldo G; Trevisan CM; Christofolini DM; Barbosa CP; Bianco B
    Genet Test Mol Biomarkers; 2017 May; 21(5):328-333. PubMed ID: 28410456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of FSHR variants and antimüllerian hormone in infertility patients with a reduced ovarian response to gonadotropin stimulation.
    Binder H; Strick R; Zaherdoust O; Dittrich R; Hamori M; Beckmann MW; Oppelt PG
    Fertil Steril; 2012 May; 97(5):1169-75.e1. PubMed ID: 22401810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Supplementation with human menopausal gonadotropin in the gonadotropin-releasing hormone antagonist cycles of women with high AMH: Pregnancy outcomes and serial hormone levels.
    Chen LH; Chin TH; Huang SY; Yu HT; Chang CL; Huang HY; Wang HS; Soong YK; Wu HM
    Taiwan J Obstet Gynecol; 2021 Jul; 60(4):739-744. PubMed ID: 34247817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients.
    Arce JC; La Marca A; Mirner Klein B; Nyboe Andersen A; Fleming R
    Fertil Steril; 2013 May; 99(6):1644-53. PubMed ID: 23394782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Mullerian hormone is a better marker than inhibin B, follicle stimulating hormone, estradiol or antral follicle count in predicting the outcome of in vitro fertilization.
    Kunt C; Ozaksit G; Keskin Kurt R; Cakir Gungor AN; Kanat-Pektas M; Kilic S; Dede A
    Arch Gynecol Obstet; 2011 Jun; 283(6):1415-21. PubMed ID: 21562964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Ala307Thr polymorphism of the follicle-stimulating hormone receptor (FSHR) gene is associated with the dose of recombinant FSH received during IVF/ICSI treatment.
    Dieamant F; Petersen CG; Vagnini LD; Petersen B; Ricci J; Nicoletti A; Zamara C; Oliani AH; Oliveira JBA; Franco JG
    JBRA Assist Reprod; 2023 Mar; 27(1):78-84. PubMed ID: 36995260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FSHB -211 G>T is a major genetic modulator of reproductive physiology and health in childbearing age women.
    Rull K; Grigorova M; Ehrenberg A; Vaas P; Sekavin A; Nõmmemees D; Adler M; Hanson E; Juhanson P; Laan M
    Hum Reprod; 2018 May; 33(5):954-966. PubMed ID: 29617818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of prognostic modelling of high and low ovarian response to ovarian stimulation for IVF.
    Scheinhardt MO; Lerman T; König IR; Griesinger G
    Hum Reprod; 2018 Aug; 33(8):1499-1505. PubMed ID: 30007353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AMH and AMHR2 polymorphisms and AMH serum level can predict assisted reproduction outcomes: a cross-sectional study.
    Peluso C; Fonseca FL; Gastaldo GG; Christofolini DM; Cordts EB; Barbosa CP; Bianco B
    Cell Physiol Biochem; 2015; 35(4):1401-12. PubMed ID: 25790842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist--gonadotropin treatment.
    Peñarrubia J; Fábregues F; Manau D; Creus M; Casals G; Casamitjana R; Carmona F; Vanrell JA; Balasch J
    Hum Reprod; 2005 Apr; 20(4):915-22. PubMed ID: 15665015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian response prediction in GnRH antagonist treatment for IVF using anti-Müllerian hormone.
    Hamdine O; Eijkemans MJ; Lentjes EW; Torrance HL; Macklon NS; Fauser BC; Broekmans FJ
    Hum Reprod; 2015 Jan; 30(1):170-8. PubMed ID: 25355590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Müllerian hormone dynamics during GNRH-antagonist short protocol for IVF/ICSI in women with varying ovarian reserve levels.
    Melado Vidales L; Fernández-Nistal A; Martínez Fernández V; Verdú Merino V; Bruna Catalán I; Bajo Arenas JM
    Minerva Ginecol; 2017 Apr; 69(2):128-134. PubMed ID: 27310675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.